
Oral Azvudine (FNC) Tablets in Patients infected with SARS-CoV-2 Omicron Variant: A Retrospective Cohort Study

Wenmei Chen^{1,4,5,*}, Honggang Xu^{3,*}, Lei Hong^{1,4,5,*}, Ran Yang^{1,4,5}, Caiqiu Peng^{1,4,5},
Guiqiang Wang^{2,6,7,#}, Wei Li^{1,4,5,#}

1. Department of Respiratory Disease, the First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.
2. Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
3. Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
4. Center for Clinical Medicine of Respiratory Disease(tumor), Bengbu, Anhui, 233004, China.
5. Provincial Key Laboratory of Respiratory Disease, Bengbu, Anhui, 233004, China.
6. Department of Infectious Diseases, Peking University International Hospital, Beijing, 102206, China.
7. Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, 100034, China.

* **These authors have contributed equally to this work.**

Correspondence to: Prof. Wei Li, Email:bbmcliwei@126.com, Tel: +86 552 3086132 Fax: +86 552 3070260, Department of Respiratory Disease, the First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road Bengbu, Anhui, 233004, PR China or Prof. Guiqiang Wang, E-mail: john131212@111.com, Department of Infectious Disease, Peking University First Hospital, No. 8 Xishiku Street, Beijing, 100034, PR China.

Abstract

Background: There is a lack of data on the efficacy of oral Azvudine in Coronavirus Disease treatment. This study aimed to assess the association between Azvudine treatment and clinical outcomes in a cohort of patients infected with the SARS-CoV-2 Omicron variant.

Methods: This is a retrospective study conducted in two mobile cabin hospitals. All consecutive patients with a diagnosis of COVID-19 admitted from August to October 2022 were included in the study. Linear regression models and Cox proportional hazards models were used to assess the association between Azvudine treatment and time to obtain the first negative nucleic acid test results.

Results: A total of 207 patients were analyzed, of whom 166 patients (80.2%) received Azvudine treatment after hospitalization, and the rest did not. Linear regression models showed that Azvudine treatment was associated with reduced time to obtain the first negative nucleic acid test results after adjusting for age and gender [mean difference = -1.658 ; 95% CI: -2.772 to -0.544 , $P = 0.0039$]. The multivariable Cox analysis conforms to the results from the linear regression model (hazard ratio = 1.461 ; 95% CI: 1.01 to 2.11 , $P = 0.044$).

Conclusion: Azvudine treatment was associated with reduced virus shedding time. Further studies are needed to confirm our findings.

Keywords: SARS-CoV-2; Omicron variant; Azvudine; Virus shedding time; Prognosis

Introduction

The Coronavirus Disease (COVID-19) epidemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading across the world [1, 2]. In November 2021, the Omicron variant (B.1.1.529) of SARS-CoV-2 emerged and quickly exceeded other variants of concerns (VOCs) and became the dominating one[3]. The high number of mutations in the spike protein promotes immune evasion [4], leading to enhanced transmission ability and weakened protective effects from neutralizing antibodies [5].

Antiviral drugs are considered a potential therapy and are recommended in guidelines [6, 7]. Azvudine (also known as FNC), a 4'-modified nucleoside drug candidate [8], is the first domestic-developed oral antiviral agent in China[9]. A pilot study compared Azvudine with standard antiviral treatment in 20 patients with mild and moderate COVID-19, and found that oral Azvudine tablets could shorten the viral shedding time [10]. However, this study has a limited number of patients and only focuses on mild and moderate COVID-19 patients.

Given the scarcity of data on the oral Azvudine tablets in patients infected with the SARS-CoV-2 Omicron variant, we conducted a retrospective study to assess the association between Azvudine treatment and clinical outcomes in a cohort of patients infected with SARS-CoV-2 Omicron variant.

Methods

Study design and patients

This study is a multicenter, retrospective study conducted in Luqiong and Naidong mobile cabin hospitals, which are novel concept hospitals for treating non-critical COVID-19 patients. This study was approved by the institutional review board of the First Affiliated Hospital of Bengbu Medical College with a waiver of consent for the the retrospective observational design (No. 2020KY112, 2020KY016). All consecutive patients with a diagnosis of COVID-19 admitted from August to October 2022 were included in the study. SARS-CoV-2 Omicron variant infection was confirmed by RT-PCR via daily nasopharyngeal swabs. All eligible patients were divided into those who received Azvudine (Azvudine group) and those who received exclusive supportive treatment (control group).

Outcomes and definitions

The primary outcome is the time from the first dose of Azvudine (or supportive treatment) to the time when the first negative nucleic acid result was obtained. The nucleic acid test with samples obtained by nasopharyngeal swabs was repeated daily. The secondary outcomes include the nucleic acid conversion rate within the first five days after drug treatment and during the hospitalization, the total course of COVID-19, recurrence of positive nucleic acid results during the first month after hospital discharge, length of hospital stay, and incidence of adverse events. The total course of COVID-19 was defined as the interval between the diagnosis of Omicron variant

infection and when the first negative nucleic acid result was obtained. The different clinical categories of COVID-19 were defined according to the Chinese Diagnosis and Treatment Program for Novel Coronavirus Pneumonia (Ninth Edition). The definition of mild COVID-19 was patients with mild clinical symptoms and without signs of pneumonia in imaging, whereas moderate COVID-19 was defined when patients had fever, respiratory symptoms, and signs of pneumonia in imaging.

Data Collection

Demographic and clinical characteristics, including age, gender, clinical category, risk factors for critical COVID-19, and symptoms at admission, were collected from electronic medical records. Daily cycle threshold of nucleic acid and adverse events during the Azvudine treatment were also collected.

Statistical Analysis

All data analyses were performed using R software (version 4.1.0). The distribution of continuous variables was examined for normality using the Shapiro-Wilk test. Continuous variables were expressed as median (interquartile range) and analyzed by Mann–Whitney U test. Categorical variables were expressed as absolute numbers (percentage) and compared by Pearson's chi-square or Fisher exact test as indicated.

Linear regression models were used to investigate the association between Azvudine treatment and time to obtain the first negative nucleic acid test results in unadjusted and adjusted models. Subgroup analyses were performed according to age

(≤ 60 and > 60 years old), and clinical categories (asymptomatic and mild-to-moderate COVID-19). Mean differences and 95% CIs were calculated. We also applied the Cox proportional hazards models to assess the relationship between Azvudine treatment and the rate of nucleic acid negative conversion. Variables, including age, gender, group (Azvudine or control group), and clinical categories, were tested by univariable and multivariable analysis. Pearson's correlation coefficient and the variance inflation factor were used to detect the presence of multicollinearity among variables included in the regression model. Kaplan-Meier methods were used to display curves for time to the first negative nucleic acid test within the first five days after drug treatment. A log-rank test was conducted to compare the time to the first negative nucleic acid test curves of the two groups. A two-tailed p-value of < 0.05 was considered significant.

Results

Patients enrolment and characteristics

A total of 207 patients were included in the analysis (Figure 1). Among this cohort, 166 patients (80.2%) received Azvudine treatment after admission. The demographic and clinical characteristics of the study patients are summarized in Table 1. Patients in the Azvudine group were older than the control group [29 (7-47) vs. 36 (27-47), $P=0.003$]. The majority of the study subjects were asymptomatic (79/207, 38.2%) or mild COVID-19 (111/207, 53.6%), and had no risk factors for critical COVID-19 (169/207, 81.6%).

The most common signs or symptoms at the onset of COVID-19 were fever

(36/207, 17.4%), cough (46/207, 22.2%), and pharyngalgia (49/207, 23.7%). There were no significant differences in gender, clinical categories, risk factors for critical COVID-19, and signs or symptoms between groups.

Clinical outcomes and adverse events

The clinical outcomes and adverse events of the study patients are shown in Table 2. All patients survived and obtained negative nucleic acid test results before discharge. The median course of SARS-CoV-2 infection and length of hospital stay were 8 (IQR: 7-11) days and 12 (IQR: 9-15) days, respectively. A total of 13 patients had a recurrence of positive nucleic acid test, including four patients in the control group (9.8%) and nine in the Azvudine group (5.4%). Patients receiving Azvudine treatment had a shorter time from initiation of treatment to the first negative nucleic acid test results [5 (IQR: 1-7) vs 6 (IQR: 5-7) days, $P = 0.001$]. Nine patients had adverse events, and nausea, diarrhea, and vomiting were the most common adverse events in the Azvudine group.

Association between drugs treatment and first nucleic acid negative conversion

As shown in Table3, Azvudine treatment was associated with reduced time to obtain the first negative nucleic acid test results after adjusting for age and gender [mean difference = -1.658 ; 95% CI: -2.772 to -0.544 , $P = 0.0039$]. In subgroup analyses, the association remained significant in younger patients (≤ 60 years old, $P = 0.0092$), but not in elderly patients (> 60 years old, $P = 0.0986$). Moreover, the

efficacy of Azvudine was not impacted by the disease categories (asymptomatic or mild-to-moderate COVID-19).

The multivariable Cox analysis also revealed that the Azvudine treatment was associated with an increased rate of nucleic acid negative conversion during the hospitalization (HR = 1.461; 95% CI, 1.01 to 2.11, P = 0.044) (Table 4). Additionally, the Kaplan–Meier survival curves illustrated Azvudine treatment could increase the nucleic acid negative conversion rate within the first five days after drug treatment (Figure 2, $P_{\text{log-rank test}} = 0.001$).

Discussion

This study found that most patients infected by the Omicron variant had asymptomatic or mild COVID-19. Moreover, Azvudine treatment was associated with a reduced time to obtain the first negative nucleic acid test results. To the best of our knowledge, this is the largest study to evaluate the effect of oral Azvudine in patients infected with the SARS-CoV-2 Omicron variant.

Our results are consistent with an observational study that the majority of patients infected with the SARS-CoV-2 Omicron variant are asymptomatic or mild COVID-19 [11], suggesting a reduced pathogenicity of Omicron variants [12, 13]. Nevertheless, the unique biological characteristics of Omicron variants increase the transmissibility, particularly in asymptomatic COVID-19 patients [14]. These patients may recover faster if they receive timely antiviral agents. However, there is a lack of effective antiviral agents, which may accelerate the spread of the pandemic and account for a

large cumulative expense of medical resources.

Azvodine is a promising antiviral agent for COVID-19 treatment [15]. A previous animal study showed that oral Azvodine (0.07 mg/kg, qd) could reduce the viral load and alleviate inflammation response or organ damage [16]. Recently, a pilot study recruited 20 patients with mild and moderate COVID-19 and randomly assigned them to receive Azvodine (n = 10) or standard antiviral treatment (n =10). The results showed that oral Azvodine tablets could shorten the viral shedding time compared with standard antiviral treatment [10], which is similar to our study. Additionally, a randomized, single-arm clinical trial showed that oral Azvodine (5 mg, qd) could achieve 100% viral nucleic acid conversion in 3.29 ± 2.22 days (IQR: 1–9 days) and 100% hospital discharge in 9.00 ± 4.93 days (IQR: 2–25 days) [16].

On the contrary, other antiviral agents did not exhibit satisfying results. Remdesivir can directly inhibit the activity of SARS-CoV-2 in vitro [17], but a recent report about the compassionate use of remdesivir for patients with severe COVID-19 showed that clinical improvement was only observed in 68% of patients [18]. Nirmatrelvir is approved by the Food and Drug Administration for the treatment of mild-to-moderate COVID-19 in preventing severe progression, and a large retrospective cohort study showed that Nirmatrelvir only reduced the rate of severe COVID-19 in patients aged ≥ 65 years old [19]. Our subgroup analysis showed that Azvodine might also be effective in patients under 60 years old.

The strength of this study is that this is the largest study to investigate the effect of Azvodine treatment in patients infected with the SARS-CoV-2 Omicron variant.

However, several limitations should be addressed. First, although several attempts were made to control the unbalance of demographic and clinical characteristics between groups, unmeasured confounders cannot be adjusted. Moreover, we did not collect data regarding routine laboratory tests and other variables of clinical improvements. Additionally, owing to the retrospective nature of this study, a causal relationship cannot be inferred, and the results should be interpreted with caution.

Conclusion

Our study showed that Azvudine treatment was associated with reduced time to obtain the first negative nucleic acid test results. Larger randomized clinical trials are needed to assess the impact of oral Azvudine tablets on clinical improvement in patients infected with the SARS-CoV-2 Omicron variant or future variants.

Declarations

Acknowledgment: None.

Competing interest: The authors declare no competing interests.

Authors' contributions: WL, GQW equally contributed to the conception and design of the research. WMC, HGX, LH, RY and CQP performed the research and analyzed the data. WMC, HGX and LH wrote the manuscript and interpretation of data. All authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.

Ethics statement: This study was approved by the institutional review board of the First Affiliated Hospital of Bengbu Medical College with a waiver of consent for the retrospective observational design (No. 2020KY112, 2020KY016).

Availability of data and materials statement: The datasets are not publicly available due to privacy but are available from the corresponding author on reasonable request.

Funding: This study was funded by COVID-19 Emergency Project of the Ministry of Science and Technology (2020YFC0846800) and Science Research Project of Bengbu Medical College (KJ2021A0791).

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* **382**, 727-33 (2020).
2. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* **5**, 536-44 (2020).
3. Brussow H. COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. *Microb Biotechnol* **15**, 1927-39 (2022).
4. McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. *Science* **375**, 864-8 (2022).
5. Huang M, Wu L, Zheng A, Xie Y, He Q, Rong X, et al. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. *Immunity* **55**, 1501-14 e3 (2022).
6. Xu Y, Chen Y, Tang X. Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China. *Glob Health Med* **2**, 66-72 (2020).
7. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda (MD)2021.
8. Chang J. 4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives. *Acc Chem Res* **55**, 565-78 (2022).
9. Yu B, Chang J. The first Chinese oral anti-COVID-19 drug Azvudine launched. *Innovation (Camb)* **3**, 100321 (2022).
10. Ren Z, Luo H, Yu Z, Song J, Liang L, Wang L, et al. A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. *Adv Sci (Weinh)* **7**, e2001435 (2020).
11. Xu H, Li H, You H, Zhang P, Li N, Jiang N, et al. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: Real-world study in Jilin Province, China. *Emerg Microbes Infect* 1-30 (2022).

12. Lin YF, Wu X, Li Y, Bian J, Li K, Jiang Y, et al. Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China. *J Med Virol* (2022).
13. Ying-Hao P, Yuan-Yuan G, Hai-Dong Z, Qiu-Hua C, Xue-Ran G, Hai-Qi Z, et al. Clinical characteristics and analysis of risk factors for disease progression of patients with SARS-CoV-2 Omicron variant infection: A retrospective study of 25207 cases in a Fangcang hospital. *Front Cell Infect Microbiol* **12**, 1009894 (2022).
14. Guo Y, Han J, Zhang Y, He J, Yu W, Zhang X, et al. SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. *Front Immunol* **13**, 877101 (2022).
15. Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. *Signal Transduct Target Ther* **5**, 236 (2020).
16. Zhang JL, Li YH, Wang LL, Liu HQ, Lu SY, Liu Y, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. *Signal Transduct Target Ther* **6**, 414 (2021).
17. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* **30**, 269-71 (2020).
18. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med* **382**, 2327-36 (2020).
19. Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. *N Engl J Med* **387**, 790-8 (2022).

Figure Legends

Figure 1. Flowchart of study subjects

Figure 2. Kaplan–Meier curves of nucleic acid testing negativity within the first five days after drug treatment

Table 1. Demographic and clinical characteristics of study patients

	Control group (N = 41)	Azvadine group (N = 166)	P value
Age, y	29 (7-47)	36 (27-47)	0.003
Gender			0.525
Female	24 (58.5)	88 (53)	
Male	17 (41.5)	78 (47)	
Clinical category			0.152
Asymptomatic	20 (48.8)	59 (35.5)	
Mild	18 (43.9)	93 (56)	
Moderate	3 (7.3)	14 (8.4)	
Total number of risk factors for critical COVID-19			0.255
≥ 1	5 (12.2)	33 (19.9)	
None	36 (87.8)	133 (80.1)	
Risk factors for critical COVID-19			
> 60 years old	2 (4.9)	12 (7.2)	0.85
Heavy smokers	3 (7.3)	13 (7.8)	0.912
Hypertension	1 (2.4)	6 (3.6)	0.709
Coronary disease	1 (2.4)	1 (0.6)	0.358
Diabetes	1 (2.4)	2 (1.2)	0.486
Signs and symptoms			
Fever	7 (17.1)	29 (17.5)	0.952
Cough	8 (19.5)	38 (22.9)	0.641
Myalgia	2 (4.9)	8 (4.8)	0.987
Pharyngalgia	7 (17.1)	42 (25.3)	0.267
Fatigue	0 (0)	2 (1.2)	1
Headache	4 (9.8)	18 (10.8)	0.84
Abdominal pain	0 (0)	2 (1.2)	1
Nausea	2 (4.9)	1 (0.6)	0.101
Diarrhea	2 (4.9)	2 (1.2)	0.176

Nasal stuffiness	1 (2.4)	1 (0.6)	0.358
Dyspnoea	0 (0)	1 (0.6)	1
Rhinorrhoea	0 (0)	6 (3.6)	0.217
Expectoration	1 (2.4)	5 (3)	0.845

Data are presented as n (%) or median (interquartile range).

Table 2. Clinical outcomes and adverse events of study patients

	Control group (N = 41)	Azvudine group (N = 166)	P value
Proportion of nucleic acid negative conversion	41 (100)	166 (100)	
Time from drugs treatment to first nucleic acid-negative conversion	6 (5-7)	5 (1-7)	0.001
Total course of COVID-19	8 (7-13)	9 (7-11)	0.945
Recurrence of nucleic acid positive	4 (9.8)	9 (5.4)	0.306
Length of hospital stay	12 (10-14)	12 (8-15)	0.793
Proportion of subjects with adverse events	0 (0)	9 (5.4)	0.273
Adverse events			
Nausea	0 (0)	6 (3.6)	0.474
Diarrhea	0 (0)	6 (3.6)	0.474
Vomiting	0 (0)	6 (3.6)	0.474
Stomachache	0 (0)	2 (1.2)	1

Data are presented as n (%) or median (interquartile range).

Table 3. Relationship between Azvudine treatment and time to obtain the first negative nucleic acid test results

	Mean difference (95% CI)	P value
Total population		
Unadjusted model	-1.892 (-3.038 - -0.745)	0.0014
Adjusted model*	-1.658 (-2.772 - -0.544)	0.0039
Subgroup population		
Patients aged ≤ 60		
Unadjusted model	-1.785 (-2.986 - -0.594)	0.004
Adjusted model*	-1.552 (-2.708 - -0.397)	0.0092
Patients aged > 60		
Unadjusted model	-3.328 (-8.077 - 1.421)	0.1996
Adjusted model*	-3.866 (-8.097 - 0.366)	0.0986
Patients with asymptomatic COVID-19		
Unadjusted model	-2.035 (-3.955 - -0.116)	0.0411
Adjusted model*	-1.888 (-3.607 - -0.17)	0.0344
Patients with mild-to-common COVID-19		
Unadjusted model	-1.651 (-3.144 - -0.159)	0.032
Adjusted model*	-1.528 (-3.023 - -0.033)	0.0473

* adjusted for age and gender.

Table 4. Cox proportional hazards model variables for the rate of nucleic acid negative conversion during hospitalization

	Univariable analysis		Multivariable analysis	
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Age	0.999 (0.991-1.007)	0.849	0.997 (0.988-1.006)	0.518
Group				
Control group	Reference		Reference	
Azvodine group	1.407 (0.988-2.004)	0.058	1.461 (1.01-2.113)	0.044
Gender				
Female	Reference		Reference	
Male	1.078 (0.818-1.421)	0.594	1.086 (0.823-1.434)	0.56
Clinical category				
Asymptomatic	Reference		Reference	
Mild	1.004 (0.752-1.341)	0.978	0.969 (0.723-1.299)	0.833
Moderate	0.918 (0.543-1.554)	0.751	0.92 (0.535-1.582)	0.764

All screened patients
(n = 266)

- Patients excluded (n = 59)
- Misinformation of the first nucleic acid positive (n = 27)
 - Received treatment before this admission (n = 2)
 - Missing nucleic acid data (n = 18)
 - Received treatment after nucleic acid negativity conversion (n = 12)

Total eligible patients
(n = 207)

No Azvudine treatment
(n = 41)

Azvudine treatment
(n = 166)

